Free Trial

Progyny (PGNY) Stock Forecast & Price Target

Progyny logo
$16.95 +2.24 (+15.23%)
(As of 02:46 PM ET)

Progyny - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
9
Buy
4

Based on 13 Wall Street analysts who have issued ratings for Progyny in the last 12 months, the stock has a consensus rating of "Hold." Out of the 13 analysts, 9 have given a hold rating, and 4 have given a buy rating for PGNY.

Consensus Price Target

$25.00
47.49% Upside
According to the 13 analysts' twelve-month price targets for Progyny, the average price target is $25.00. The highest price target for PGNY is $43.00, while the lowest price target for PGNY is $17.00. The average price target represents a forecasted upside of 47.49% from the current price of $16.95.
Get the Latest News and Ratings for PGNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Progyny and its competitors.

Sign Up

PGNY Analyst Ratings Over Time

TypeCurrent Forecast
12/28/23 to 12/27/24
1 Month Ago
11/28/23 to 11/27/24
3 Months Ago
9/29/23 to 9/28/24
1 Year Ago
12/28/22 to 12/28/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
9 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.00$25.42$27.73$47.00
Forecasted Upside47.49% Upside64.19% Upside65.04% Upside24.50% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

PGNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PGNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Progyny Stock vs. The Competition

TypeProgynyMedical CompaniesS&P 500
Consensus Rating Score
2.31
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside69.95% Upside25,716.25% Upside13.32% Upside
News Sentiment Rating
Positive News

See Recent PGNY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/2/2024JPMorgan Chase & Co.
3 of 5 stars
 Reiterated RatingOverweight ➝ Neutral$22.00 ➝ $17.00+12.21%
11/14/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$30.00 ➝ $17.00+22.30%
11/13/2024Bank of America
3 of 5 stars
 Lower TargetBuy ➝ Buy$22.00 ➝ $21.00+49.15%
11/13/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$18.00 ➝ $17.00-1.05%
11/13/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$26.00 ➝ $19.00+10.59%
10/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.00+53.56%
9/19/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$31.00 ➝ $24.00+45.81%
9/19/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform ➝ Market Perform$25.00 ➝ $21.00-14.08%
9/19/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Davides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/7/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Larsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/10/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Schoenhaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Sector Weight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:05 PM ET.


PGNY Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Progyny is $25.00, with a high forecast of $43.00 and a low forecast of $17.00.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PGNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGNY, but not buy additional shares or sell existing shares.

According to analysts, Progyny's stock has a predicted upside of 47.49% based on their 12-month stock forecasts.

Progyny has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, JPMorgan Chase & Co., and Truist Financial in the past 90 days.

Analysts like Progyny less than other "medical" companies. The consensus rating for Progyny is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PGNY compares to other companies.


This page (NASDAQ:PGNY) was last updated on 12/27/2024 by MarketBeat.com Staff
From Our Partners